Results 21 to 30 of about 910,494 (304)

Hereditary severe insulin resistance syndrome: Pathogenesis, pathophysiology, and clinical management

open access: yesGenes and Diseases, 2023
Severe insulin resistance has been linked to some of the most globally prevalent disorders, such as diabetes mellitus, nonalcoholic fatty liver disease, polycystic ovarian syndrome, and hypertension. Hereditary severe insulin resistance syndrome (H-SIRS)
Junaid Iqbal   +9 more
doaj   +1 more source

18F-Sodium Fluoride PET as a Diagnostic Modality for Metabolic, Autoimmune, and Osteogenic Bone Disorders: Cellular Mechanisms and Clinical Applications

open access: yesInternational Journal of Molecular Sciences, 2021
In a healthy body, homeostatic actions of osteoclasts and osteoblasts maintain the integrity of the skeletal system. When cellular activities of osteoclasts and osteoblasts become abnormal, pathological bone conditions, such as osteoporosis, can occur ...
P.S.U. Park   +5 more
semanticscholar   +1 more source

Ferroptosis and Its Potential Role in Metabolic Diseases: A Curse or Revitalization?

open access: yesFrontiers in Cell and Developmental Biology, 2021
Ferroptosis is classified as an iron-dependent form of regulated cell death (RCD) attributed to the accumulation of lipid hydroperoxides and redox imbalance.
Jia-Yue Duan   +13 more
doaj   +1 more source

Reactive Oxygen Species (ROS)-Responsive Biomaterials for the Treatment of Bone-Related Diseases

open access: yesFrontiers in Bioengineering and Biotechnology, 2022
Reactive oxygen species (ROS) are the key signaling molecules in many physiological signs of progress and are associated with almost all diseases, such as atherosclerosis, aging, and cancer.
Xiaoxiang Ren   +5 more
semanticscholar   +1 more source

Pharmacometrics and systems pharmacology for metabolic bone diseases.

open access: yesBritish Journal of Clinical Pharmacology, 2019
Mathematical modelling and simulation (M&S) of drug concentrations, pharmacologic effects and the (patho)physiologic systems within which they interact can be powerful tools for the preclinical, translational and clinical development of drugs.
M. Riggs, S. Cremers
semanticscholar   +1 more source

Effect of Body Surface Area on Severe Osteoporotic Fractures: A Study of Osteoporosis in Changsha China

open access: yesFrontiers in Endocrinology, 2022
Clinical vertebral fractures and femoral neck fractures are severe osteoporotic fractures that increase morbidity and mortality. Anthropometric variables are associated with an increased risk of osteoporotic fractures, but it is not clear whether body ...
Xi-Yu Wu   +9 more
doaj   +1 more source

Genetic approaches to metabolic bone diseases

open access: yesBritish Journal of Clinical Pharmacology, 2018
Metabolic bone diseases comprise a diverse group of disorders characterized by alterations in skeletal homeostasis, and are often associated with abnormal circulating concentrations of calcium, phosphate or vitamin D metabolites.
F. Hannan   +3 more
semanticscholar   +1 more source

Regulatory aspects of the development of drugs for metabolic bone diseases - FDA and EMA perspective.

open access: yesBritish Journal of Clinical Pharmacology, 2018
Regulation of medicines involves complex scientific and public health policies which are reflected in the regulatory approaches used by the European Medicines Agency and the United States Food and Drug Administration for the approval of products ...
T. Kehoe, E. Blind, Heidi Janssen
semanticscholar   +1 more source

Zoledronic acid and atorvastatin inhibit αvβ3-mediated adhesion of breast cancer cells

open access: yesJournal of Bone Oncology, 2014
Bone metastases represent common long term complications of patients with breast cancer. Zoledronic acid, an amino-bisphosphonate and mevalonate pathway inhibitor, is an established agent for the treatment of bone metastases.
Maria Wilke   +8 more
doaj   +1 more source

Gaucher disease: the role of the specialist on metabolic bone diseases.

open access: yesCLINICAL CASES IN MINERAL AND BONE METABOLISM, 2015
According to European legislation, a disease can be considered rare or "orphan" when it affects less than 1 subject of 2000 (1). Often these diseases affecting the pediatric age, are complex diseases and chronically debilitating and for this motive need ...
L. Masi, M. Brandi
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy